# A Study of RC118 in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid Tumors

> **NCT05205850** · PHASE1,PHASE2 · RECRUITING · sponsor: **RemeGen Co., Ltd.** · enrollment: 135 (estimated)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** RC118-ADC

## Key facts

- **NCT ID:** NCT05205850
- **Lead sponsor:** RemeGen Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-03-03
- **Primary completion:** 2025-09-30
- **Final completion:** 2025-12-01
- **Target enrollment:** 135 (ESTIMATED)
- **Last updated:** 2025-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05205850

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05205850, "A Study of RC118 in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid Tumors". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT05205850. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*